Skip to content

Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers

Assessment of Genomic Alterations and Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06133790
Acronym
HPVNGS
Enrollment
0
Registered
2023-11-15
Start date
2024-01-01
Completion date
2024-06-30
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Brief summary

Squamous cell cancers of the head and neck are classically correlated to excessive consumption of alcohol and tobacco and have a rather poor prognosis. However, the incidence of Head and Neck cancers in patients without alcohol-smoking risk factor has continued to increase in recent years, in relation to more and more frequent HPV contamination. Some studies show a difference in the expression of certain genes within the two groups of tumors (HPV+ and HPV-) including some that confer sensitivity to certain chemotherapies and others to radiotherapy. However, patients with HPV+ Head and Neck cancers are treated according to the same referential as HPV- Head and Neck cancers. There is therefore a real need for studies identifying predictive markers in order to be able to offer patients a more effective suitable and less invasive treatment.

Detailed description

Head and neck cancers are the sixth most common cancer common worldwide causing more than 380,000 deaths each year. More than 90% of these cancers are carcinomas epidermoids arising from the mucosal surfaces of the cavity oral cavity, oropharynx and larynx. Squamous cell cancers of the head and neck are classically correlated with risk factors linked to excessive consumption of alcohol and tobacco and have a rather poor prognosis (mainly HPV (Human Papilloma Virus) negative patients). However, the incidence of Head and Neck cancers in patients without alcohol-smoking risk factor has continued to increase in recent years, in relation to more and more frequent HPV contamination. Evolution of oral sexual practices seems to be one of the explanations for the progression of these cases of oropharyngeal squamous cell carcinoma and oral cavity HPV positive. Some studies show a difference in the expression of certain genes within the two groups of tumors (HPV+ and HPV-) including some that confer sensitivity to certain chemotherapies (CCND1, TYMS) and others to radiotherapy (RBBP4). However, patients with HPV+ Head and Neck cancers are treated according to the same referential as HPV- Head and Neck cancers. There is therefore a real need for studies identifying predictive markers in order to be able to offer patients a more effective suitable and less invasive treatment. This is the context of this research project.

Interventions

GENETICPCR - Immunohistochemistry - Immunolabelling

Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors

Sponsors

GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with oropharyngeal squamous cell carcinoma or the oral cavity histologically proven. * Primary tumor for which a biopsy or excision is required available and sufficient to carry out molecular analysis

Exclusion criteria

\- Patient with Head and Neck cancer other than oropharyngeal or oral cavity squamous cells carcinomas

Design outcomes

Primary

MeasureTime frameDescription
Molecular profile of oropharyngeal or oral cavity HPV positive and negative tumors1 dayMolecular profile of tumors will be established with analysis of 87 "Hotspot" genes, full length analysis of 48 genes, copy number analysis of 43 genes and gene fusion (inter and intra genic) of 51 genes.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORJérôme PARIS, MD

Hôpital privé de Clairval

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026